Accepted for/Published in: JMIR mHealth and uHealth
Date Submitted: Oct 11, 2018
Open Peer Review Period: Oct 14, 2018 - Dec 9, 2018
Date Accepted: Feb 17, 2019
(closed for review but you can still tweet)
“Vive sin Tabaco… ¡Decídete!”: A Mobile Smoking Cessation Intervention for Mexico
ABSTRACT
Background:
Of the 14.3 million Mexicans who smoke, only a minority take advantage of evidence-based approaches to smoking cessation. Mobile health interventions have the potential to increase the reach of effective cessation interventions in Mexico and other Low- and Middle-Income Countries (LMICs).
Objective:
To assess an innovative, personalized, and interactive mobile intervention developed for Mexican smokers.
Methods:
We recruited 40 Mexican smokers to participate in Vive sin Tabaco… ¡Decídete!, a smoking cessation program that uses a tablet-based decision-support software to drive a 12-week text messaging smoking cessation program and pharmacotherapy support. Outcome measures included participant text messaging interactivity with the program, participant satisfaction, and 12-week end-of-treatment abstinence.
Results:
Average age of participants was 36 years old, primarily male (65%), with at least an undergraduate degree (62.5%). Most participants (95%) smoked daily and were interested in quitting in the next 7 days. As an indicator of participant interactivity, participants sent an average of 21 text messages during the 12-week intervention (SD=17.62). Of the 843 messages that participants sent to the program, only 96 messages (11.3%) used keywords. At 12 weeks, 16 (40%) participants were biochemically verified abstinent using intent-to-treat analysis (87.5% follow-up rate). The majority of participants (84.4%) reported being very satisfied or extremely satisfied with the program.
Conclusions:
The Vive sin Tabaco… ¡Decídete! smoking cessation mobile intervention was accepted by participants, generated high satisfaction and high text messaging interactivity, and resulted in noteworthy cessation rates at end-of-treatment. This intervention is a promising strategy for smoking cessation in LMICs. Additional testing as a formal randomized clinical trial appears warranted.
Citation
Per the author's request the PDF is not available.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.